x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Flot.bio x Philip Hemme

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the

science life sciences

All Episodes

01:14:55

Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25

Flot.bio x Philip Hemme ·

2024/12/02

We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years. We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China. ⭐️ ABOUT THE SPEAKER Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as

en-us

00:59:16

Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company...

Flot.bio x Philip Hemme ·

2024/11/18

In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech. ⭐️ ABOUT THE SPEAKER Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many

en-us

01:04:44

Szabolcs Nagy, Turbine 🇭🇺 | AI in Biotech, Simulation...

Flot.bio x Philip Hemme ·

2024/11/11

We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world. We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __ This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6 __ ⭐️ ABOUT THE SPEAKER I’ve known Szabolcs since 2017 when he

en-us

00:54:29

Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell...

Flot.bio x Philip Hemme ·

2024/10/28

We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — — Thank you to today’s sponsor, Merck, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/3AhZFUA — —

en-us

01:19:52

Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines,...

Flot.bio x Philip Hemme ·

2024/10/01

We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier.We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she

en-us

01:04:02

Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based...

Flot.bio x Philip Hemme ·

2024/09/02

We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh.We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. 🔗 LINKS MENTIONED Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019:

en-us

01:08:38

Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC...

Flot.bio x Philip Hemme ·

2024/07/15

We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis.We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. 🔗 LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized €128 Million Series B2 to

en-us

01:02:46

Otello Stampacchia, Omega Funds 🇮🇹 | Competitive...

Flot.bio x Philip Hemme ·

2024/06/28

We’re in Boston 🇺🇸 with one of the top VCs, Otello Stampacchia of Omega Funds.We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/otello-stampacchia-omega-funds/ 💸 DONATE We welcome donations from individuals and businesses to support our more content creation:

en-us

00:43:45

Christina Takke, V-Bio Ventures 🇧🇪 | Wonder VC Woman...

Flot.bio x Philip Hemme ·

2024/06/17

We’re in San Sebastián 🇪🇸 with one of the top VCs in Europe, Christina Takke from V-Bio Ventures. We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three employees and the venture creation had dropped since 2022. 🔗 LINKS MENTIONED - Lean years for company creation in Europe? - BioVox, Sep 2023 -

en-us

00:46:16

Naveed Siddiqi, Novo Holdings 🇬🇧🇩🇰 | Sharp Macro View...

Flot.bio x Philip Hemme ·

2024/05/27

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings.We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open. 💎 ABOUT THE SPEAKER Naveed has been a part of Novo Holdings since 2019 and splits his time

en-us

00:54:34

Claudia Ulbrich, Cardior 🇩🇪 | Being the Founder of a...

Flot.bio x Philip Hemme ·

2024/05/07

We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia UlbrichWe talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”. 💎 ABOUT THE SPEAKER Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer

en-us

01:15:45

Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity,...

Flot.bio x Philip Hemme ·

2024/03/26

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKER I’ve “known” Bahija for over 10

en-us

01:26:40

Edwin Moses | How to build large biotech platforms | E13

Flot.bio x Philip Hemme ·

2024/03/05

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow.💎 ABOUT THE SPEAKER Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the

en-us

01:18:34

Jens Nielsen, BII | How to make translation of life...

Flot.bio x Philip Hemme ·

2024/02/05

We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing most of Denmark’s biotech ecosystem.💎 ABOUT THE SPEAKER Jens Nielsen is one of the best in this space in Europe. Not only is he the CEO of BII, he’s

en-us

00:59:06

Sander van Deventer, VectorY & Forbion | Pioneering...

Flot.bio x Philip Hemme ·

2024/01/15

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKER Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so

en-us

01:20:13

Thomas Clozel, Owkin | What does AI Biotech really...

Flot.bio x Philip Hemme ·

2023/12/18

In an online special, we’re interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents. 💎 ABOUT THE SPEAKER Thomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasn’t sure where it would go. Now it’s a unicorn following a $180M investment from Sanofi in 2021 and has over 300 employees. 🔗 LINKS MENTIONED - Exscientia Expands Biologics

en-us

01:11:33

Marc de Garidel, Abivax | How to make two billion 💶...

Flot.bio x Philip Hemme ·

2023/12/04

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 🫶 FOLLOW US

en-us

01:44:25

Mike Ward | The Best and the Worst since the 80s in...

Flot.bio x Philip Hemme ·

2023/11/20

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s. 💎 ABOUT THE SPEAKER Mike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now Clarivate. I’ve known Mike for many years and I like how clearly he sees things while being no-bullshit and fun. 📜 TRANSCRIPT Read the full

en-us

01:21:51

Agnete Fredriksen, Nykode | Being one of the top 50...

Flot.bio x Philip Hemme ·

2023/10/31

We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her

en-us

01:12:03

Rodger Novak, CRISPR Tx | Bringing the first CRISPR...

Flot.bio x Philip Hemme ·

2023/10/24

Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgers’ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him back in 2016 at Labiotech. It’s a treat to be able to sit down with him again. 💎 ABOUT THE SPEAKER A serial entrepreneur, Rodger Novak has made it big

en-us

45 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter